iRhythm Technologies Q3 2026 Earnings Report

iRhythm Technologies EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.02
• Beat/Miss: N/A
• One Year Ago EPS: N/A

iRhythm Technologies Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $222.45 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

iRhythm Technologies Announcement Details

• Quarter: Q3 2026
• Date: 10/29/2026
• Time: After Market Closes
• Conference Call Date: Thursday, October 29, 2026
• Conference Call Time: 4:30PM ET

iRhythm Technologies (NASDAQ:IRTC), Inc. is a digital health care company focused on ambulatory cardiac monitoring and the diagnosis of cardiac arrhythmias. The company combines wearable biosensor technology, cloud-based data analysis and clinical services to help physicians detect and manage irregular heart rhythms, including atrial fibrillation.

Its principal products include the Zio monitor portfolio, which is designed for extended, continuous electrocardiogram monitoring in an easy-to-use wearable format. iRhythm’s platform collects cardiac data outside the traditional clinical setting and uses proprietary algorithms and analysis tools to identify potentially significant events for review by health care professionals. The company also provides reporting and related support services that assist clinicians in interpreting monitoring results and making treatment decisions.

Founded in 2006 and headquartered in San Francisco, iRhythm primarily serves health care providers and patients in the United States. The company has also expanded availability of its technology and services into select international markets, including the United Kingdom. iRhythm’s products are used across cardiology, primary care and other clinical settings where extended monitoring can support the evaluation of suspected or previously undiagnosed arrhythmias.